Table 4

1-Year Clinical Outcomes in the Intention-to-Treat Study Population

Total Population (n = 1,387)ZES Resolute (n = 695)EES Xience V (n = 692)Difference(95% CI)p Value
Target vessel failure113 (8.1)57 (8.2)56 (8.1)0.1 (−2.8 to 3.0)0.94
Death
 Any cause29 (2.1)15 (2.2)14 (2.0)0.1 (−1.3 to 1.6)0.86
 Cardiac cause17 (1.2)7 (1.0)10 (1.4)−0.4 (−1.6 to 0.7)0.46
Target vessel-related MI
 Any64 (4.6)32 (4.6)32 (4.6)0.0 (−2.2 to 2.2)0.99
 Q-wave11 (0.8)5 (0.7)6 (0.9)−0.1 (−1.1 to 0.8)0.76
 Non–Q-wave53 (3.8)27 (3.9)26 (3.8)0.1 (−1.9 to 2.1)0.90
 Periprocedural MI57 (4.1)29 (4.2)28 (4.0)0.1 (−2.0 to 2.2)0.91
Clinically indicated TVR
 Any42 (3.0)23 (3.3)19 (2.7)0.6 (−1.2 to 2.4)0.54
 Percutaneous33 (2.4)19 (2.7)14 (2.0)0.7 (−0.9 to 2.3)0.39
 Surgical9 (0.6)4 (0.6)5 (0.7)−0.1 (−1.0 to 0.7)0.73
Target lesion failure102 (7.4)55 (7.9)47 (6.8)1.1 (−1.6 to 3.9)0.42
Clinically indicated TLR
 Any29 (2.1)19 (2.7)10 (1.4)1.3 (−0.2 to 2.8)0.09
 Percutaneous22 (1.6)15 (2.2)7 (1.0)1.1 (−0.2 to 2.5)0.09
 Surgical7 (0.5)4 (0.6)3 (0.4)0.1 (−0.6 to 0.9)0.71
Death from cardiac causes or target vessel MI67 (4.8)34 (4.9)33 (4.8)0.1 (−2.1 to 2.4)0.92
Major adverse cardiac events132 (9.5)70 (10.1)62 (9.0)1.1 (−2.0 to 4.2)0.48
Patient-oriented composite endpoint151 (10.9)78 (11.2)73 (10.5)0.7 (−2.6 to 4.0)0.69
Definite ST (0–360 days)
 All patients4 (0.3)4 (0.6)0 (0)0.6 (0.0 to 1.1)0.12
 Acute (0–1 day)0 (0)0 (0)0 (0)
 Subacute (2–30 days)1 (0.1)1 (0.1)0 (0)0.1 (−0.1 to 0.4)1.00
 Late (31–360 days)3 (0.2)3 (0.4)0 (0)0.4 (0.0 to 0.9)0.25
Probable ST (0–360 days)
 All patients10 (0.7)2 (0.3)8 (1.2)−0.9 (−1.8 to 0.0)0.06
 Acute (0–1 day)4 (0.3)1 (0.1)3 (0.4)−0.3 (−0.9 to 0.3)0.37
 Subacute (2–30 days)4 (0.3)0 (0.0)4 (0.6)−0.6 (−1.1 to 0.0)0.06
 Late (31–360 days)2 (0.1)1 (0.1)1 (0.1)0.0 (−0.4 to 0.4)1.00
ST (0–360 days)
 Possible6 (0.4)4 (0.6)2 (0.3)0.3 (−0.4 to 1.0)0.69
 Definite or probable14 (1.0)6 (0.9)8 (1.2)−0.3 (−1.3 to 0.8)0.59
 Definite, probable, or possible20 (1.4)10 (1.4)10 (1.4)0.0 (−1.3 to 1.3)0.99

Values are n (%).

CI = confidence interval; TVR = target vessel revascularization; ST = stent thrombosis; other abbreviations as in Table 1.

  • Major adverse cardiac events are a composite of all-cause death, any myocardial infarction (MI), emergent coronary artery bypass surgery, or clinically indicated target lesion revascularization (TLR).

  • Patient-oriented composite endpoint is a composite of endpoint of all-cause death, any MI, or any revascularization.